环磷腺苷葡胺治疗小儿病毒性心肌炎效果及对心脏功能康复情况的影响

doi:10.3760/cma.j.issn.1007-1245.2023.19.007

摘要/Abstract

摘要：

目的　观察环磷腺苷葡胺治疗小儿病毒性心肌炎的效果及对心脏功能康复情况的影响。方法　本文为前瞻性研究，病例纳入时间为2021年1月至2022年12月，研究对象为南阳医学高等专科学校第一附属医院119例病毒性心肌炎患儿，通过随机数字表法对入组患儿进行分组，分为观察组（60例）和对照组（59例）。对照组中男34例，女25例，年龄（9.02±2.17）岁，予以常规治疗；观察组中男32例，女28例，年龄（9.25±2.23）岁，采用环磷腺苷葡胺配合常规治疗。比较两组患儿治疗前后的免疫功能、心肌损伤标志物及心功能指标改善情况，统计并对比两组患儿治疗后的药物相关不良反应发生情况。采用独立样本t检验、配对t检验、χ²检验。结果　治疗前，两组患儿的免疫功能、心肌损伤标志物、心功能指标差异均无统计学意义（均P>0.05）。治疗后，观察组的T淋巴细胞分化抗原3（CD3）为（65.77±10.26）%，CD4为（43.39±10.11）%，CD8为（30.15±5.28）%，均高于对照组的（58.24±10.16）%、（37.88±10.21）%、（27.66±5.19）%，差异均有统计学意义（t=4.022、2.958、2.594，均P<0.05）。治疗后，观察组的肌酸激酶为（42.33±10.15）U/L，肌酸激酶同工酶为（43.15±10.61）U/L，乳酸脱氢酶为（85.22±10.17）U/L，均低于对照组的（49.25±10.27）U/L、（50.44±10.22）U/L、（91.22±10.46）U/L，差异均有统计学意义（t=3.697、3.816、3.173，均P<0.05）。治疗后，观察组的心脏指数为（3.37±0.88）L/（min·m²），心室短轴缩短率为（38.25±8.41）%，射血分数为（66.78±10.62）%，均高于对照组的（2.72±0.65）L/（min·m²）、（33.41±8.26）%、（60.32±10.27）%，差异均有统计学意义（t=4.577、3.167、3.372，均P<0.05）。治疗后，观察组的药物相关不良反应总发生率为8.33%（5/60），略高于对照组的6.78%（4/59），差异无统计学意义（χ²=0.172，P=0.678）。结论　环磷腺苷葡胺结合常规治疗能有效改善病毒性心肌炎患儿的免疫功能并缓解心肌损伤，在有效促进患儿心脏功能康复的同时，并未明显增强不良反应发生风险。

关键词:

病毒性心肌炎, 环磷腺苷葡胺, 心肌损伤, 免疫功能

Abstract:

Objective　To observe the effect of cyclic adenosine glucosamine on viral myocarditis in children and its influence on the recovery of cardiac function. Methods　This article was a prospective study. A total of 119 children with viral myocarditis in the First Affiliated Hospital of Nanyang Medical College from January 2021 to December 2022 were divided into an observation group (60 cases) and a control group (59 cases) by the random number table method. In the control group, 34 males and 25 females, aged (9.02±2.17) years, were given routine treatment; in the observation group, 32 males and 28 females, aged (9.25±2.23) years, were treated with cyclic adenosine glucosamine combined with routine treatment. The improvement of immune function, myocardial injury markers, and cardiac function indexes before and after treatment were compared between the two groups, and the occurrence of drug-related adverse reactions after treatment was statistically analyzed and compared between the two groups. Independent sample t test, paired t test, and χ² test were used. Results　Before treatment, there were no statistically significant differences in the immune function, myocardial injury markers, and cardiac function indicators between the two groups (all P>0.05). After treatment, the CD3, CD4, and CD8 in the observation group were (65.77±10.26)%, (43.39±10.11)%, and (30.15±5.28)%, which were higher than those in the control group [(58.24±10.16)%, (37.88±10.21)% and (27.66±5.19)%], with statistically significant differences (t=4.022, 2.958, and 2.594; all P<0.05). After treatment, the levels of creatine kinase, creatine kinase isoenzyme, and lactate dehydrogenase in the observation group were (42.33±10.15) U/L, (43.15±10.61) U/L, and (85.22±10.17) U/L, respectively, which were lower than those in the control group [(49.25±10.27) U/L, (50.44±10.22) U/L, and (91.22±10.46) U/L], with statistically significant differences (t=3.697, 3.816, and 3.173; all P<0.05). After treatment, the cardiac index of the observation group was (3.37±0.88) L/(min·m²), the ventricular short axis shortening fraction was (38.25±8.41)%, and the ejection fraction was (66.78±10.62)%, which were higher than those in the control group [(2.72±0.65) L/(min·m²), (33.41±8.26)%, and (60.32±10.27)%], with statistically significant differences (t=4.577, 3.167, and 3.372; all P<0.05). After treatment, the total incidence of drug-related adverse reactions in the observation group was 8.33% (5/60), which was slightly higher than that in the control group [6.78% (4/59)], without statistically significant difference (χ²=0.172, P=0.678). Conclusion　The combination of cyclic adenosine glucosamine and routine treatment can effectively improve the immune function and alleviate the myocardial injury in children with viral myocarditis, and has a positive effect on promoting the recovery of cardiac function in children but does not significantly increase the risk of adverse reactions.

Key words:

Viral myocarditis, Cyclic adenosine glucosamine, Myocardial injury, Immune function

苏丹卫梦珂.

环磷腺苷葡胺治疗小儿病毒性心肌炎效果及对心脏功能康复情况的影响 [J]. 国际医药卫生导报, 2023, 29(19): 2692-2696.

参考文献

[1] Olejniczak M, Schwartz M, Webber E, et al. Viral myocarditis-incidence, diagnosis and management[J]. J Cardiothorac Vasc Anesth, 2020, 34(6): 1591-1601. DOI: 10.1053/j.jvca.2019.12.052.
[2] 郑诗悦,刘文秀,王丹,等. 内质网应激所致细胞死亡与柯萨奇病毒B3病毒性心肌炎[J]. 医学综述,2021,27(18):3563-3568. DOI:10.3969/j.issn.1006-2084.2021.18.006.
[3] 许祖芳,王祥贵,张永忠,等. RIP3/CaMKII信号通路对重症病毒性心肌炎小鼠心脏功能及生存曲线的影响[J]. 中华实验外科杂志,2022,39(11):2186. DOI:10.3760/cma.j.cn421213-20220512-00360.
[4] Fung RCM, Hon KL, Leung AKC. Acute myocarditis in children: an overview of treatment and recent patents[J]. Recent Pat Inflamm Allergy Drug Discov, 2020, 14(2): 106-116. DOI: 10.2174/1872213X14666200204103714.
[5] 张云燕,林威钢,杨晓鸿,等. 磷酸肌酸钠联合辅酶Q10治疗病毒性心肌炎的效果[J]. 中国妇幼保健,2021,36(10):2265-2268. DOI:10.19829/j.zgfybj.issn.1001-4411.2021. 10.023.
[6] 康锐,王蒙,胡伟,等. 环磷腺苷联合左卡尼汀治疗病毒性心肌炎的临床疗效评价[J]. 中国循证心血管医学杂志,2022,14(4):458-460. DOI:10.3969/j.issn.1674-4055.2022. 04.18.
[7] Putschoegl A, Auerbach S. Diagnosis, evaluation, and treatment of myocarditis in children[J]. Pediatr Clin North Am, 2020, 67(5): 855-874. DOI: 10.1016/j.pcl.2020. 06.013.
[8] 冯长静,刘王琰,孙晓萱,等. 心脏MR鉴别急性病毒性心肌炎与特发性炎性肌病心肌受累[J]. 实用放射学杂志,2022,38(2):222-226. DOI:10.3969/j.issn.1002-1671.2022. 02.011.
[9] Lei H, Wang D, Wang H, et al. Constrictive pericarditis caused by viral myocarditis in children: a brief report[J]. J Cardiothorac Surg, 2022, 17(1): 215. DOI: 10.1186/s13019-022-01969-6.
[10] 彭程,黎金雨,赵云. 1,6-二磷酸果糖对小儿病毒性心肌炎心肌酶谱和心功能的影响[J]. 岭南心血管病杂志,2020,26(5):585-588. DOI:10.3969/j.issn.1007-9688.2020.05.20.
[11] Basavalingappa RH, Arumugam R, Lasrado N, et al. Viral myocarditis involves the generation of autoreactive T cells with multiple antigen specificities that localize in lymphoid and non-lymphoid organs in the mouse model of CVB3 infection[J]. Mol Immunol, 2020, 8(124): 218-228. DOI: 10.1016/j.molimm.2020.06.017.
[12] 陶宝琴,王俊秋,杨慧敏. 维生素C联合免疫球蛋白对病毒性心肌炎小儿心肌重塑的影响[J]. 西北药学杂志,2021,36(5):820-824. DOI:10.3969/j.issn.1004-2407.2021.05.025.
[13] Mohamud Y, Li B, Bahreyni A, et al. Mitochondria dysfunction at the heart of viral myocarditis: mechanistic insights and therapeutic implications[J]. Viruses, 2023,15(2):351. DOI: 10.3390/v15020351.
[14] 高敏,肖明,周国. 乌司他丁联合环磷腺苷葡胺治疗病毒性心肌炎的临床疗效及对相关凋亡因子的影响[J]. 医学临床研究,2022,39(2):281-283. DOI:10.3969/j.issn.1671- 7171.2022.02.034.
[15] 孙婧,党亚南,张霄娜. 芪冬颐心口服液联合环磷腺苷葡胺对病毒性心肌炎患者心肌酶谱、细胞免疫功能及血浆心钠素水平的影响[J]. 现代中西医结合杂志,2019,28(26):2925-2928. DOI:10.3969/j.issn.1008-8849.2019.26.019.
[16] 王艳娜. 环磷腺苷葡胺对心肌炎患者谷草转氨酶水平及肌钙蛋白Ⅰ的影响[J]. 现代医药卫生,2021,37(4):653-655. DOI:10.3969/j.issn.1009-5519.2021.04.034.
[17] 朱鹏,姜盈盈,张晓娜,等. 艾司洛尔注射液联合环磷腺苷葡胺对脓毒症所致心肌损伤和心功能的影响[J]. 浙江临床医学,2020,22(8):1150-1152.
[18] 董爱芝,常以芳,姜倩倩,等. 环磷腺苷联合辅酶Q10在病毒性心肌炎患者临床治疗中的应用价值[J]. 国际医药卫生导报,2023,29(2):195-199. DOI:10.3760/cma.j.issn.1007- 1245.2023.02.012.
[19] 郑铎,郭文娟,赵雪莲,等. 益气养阴解毒方联合环磷腺苷葡胺注射液治疗病毒性心肌炎35例[J]. 河南中医,2020,40(4):581-584. DOI:10.16367/j.issn.1003-5028.2020. 04.0145.
[20] 李宁宁,朱莹莹,邓丽萍. 卡托普利联合注射用环磷腺苷葡胺对病毒性心肌炎患儿心电图及血清肌钙蛋白Ⅰ水平的影响[J]. 医药论坛杂志,2019,40(2):172-174.